Monographie - Filgrastim

Última actualización :
28/04/2024

Filgrastim

Factores que influyen sobre la estabilidad

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Accofil	Alemania, Bélgica, Gran Bretaña
Biocilin	México
Duperan	Chile
Filgen	Argentina
Foltran	Chile
Granulokine	Grecia, Italia
Hebervital	Colombia
Inmunef	Colombia
Leucosos	Colombia
Lioplim	Chile
Neupogen	Austria, Bélgica, Croacia, Dinamarca, Eslovenia, España, Estados Unidos de América, Finlandia, Francia, Gran Bretaña, Países Bajos, Polonia, Portugal, Sudafrica, Suecia, Suiza, Turquía
Neutromax	Argentina
Neutropine	Argentina
Nivestim	Alemania, Bélgica, Francia, Gran Bretaña, Noruega, Países Bajos
Ratiograstim	Alemania, Austria, Gran Bretaña, Suecia
Tevagrastim	Alemania, Gran Bretaña, Noruega, Países Bajos, Suecia, Suiza

Bibliografía : Filgrastim

	Tipo	Publicación
99	Periódico	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Periódico	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
182	Periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Periódico	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
2269	Periódico	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3128	Laboratorio	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3249	Periódico	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3256	Periódico	Burnett B, Radic I. Stability of Hospira filgrastim following changes to thermal and photic storage conditions. EJHP 2011 ; 17, 5: 49-56.
3474	Laboratorio	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3618	Laboratorio	Filgrastim (Neupogen®) - Summary of Product Characteristics Amgen 2014
3828	Póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4380	Laboratorio	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4471	Laboratorio	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019
4521	Periódico	Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Mentions Légales